Cortical and Subcortical Changes in Alzheimer\u27s Disease: A Longitudinal and Quantitative MRI Study by Su L et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Su L, Blamire AM, Watson R, He JB, Aribisala B, O'Brien JT.  
Cortical and Subcortical Changes in Alzheimer's Disease: A Longitudinal and 
Quantitative MRI Study.  
Current Alzheimer Research 2016, 13(5), 534-544. 
 
 
Copyright: 
This is the accepted manuscript of an article published in its final, definitive form by Bentham Science 
Publishers. The published manuscript is available at EurekaSelect via 
http://www.eurekaselect.com/openurl/content.php?genre=article&doi=10.2174/156720501366615
1116141416  
DOI link to article: 
http://dx.doi.org/10.2174/1567205013666151116141416  
Date deposited:   
03/06/2016 
Embargo release date: 
01 May 2017  
 1 
Cortical and subcortical changes in Alzheimer’s 1 
disease: a longitudinal and quantitative MRI study 2 
 3 
 4 
Li Su1, Andrew M. Blamire2, Rosie Watson3, Jiabao He4, Benjamin Aribisala5, 5 
and John T. O’Brien1 6 
 7 
1. Department of Psychiatry, University of Cambridge, Cambridge Biomedical 8 
Campus, Cambridge, UK;  9 
2. Institute of Cellular Medicine & Newcastle Magnetic Resonance Centre, 10 
Newcastle University, Newcastle upon Tyne, UK;  11 
3. Aged Care Department, Royal Melbourne Hospital, Parkville, Australia;   12 
4. The Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK;  13 
5. Division of Clinical Neurosciences, Western General Hospital, University of 14 
Edinburgh, Edinburgh, UK 15 
 16 
Correspondence to 17 
Dr. Li Su 18 
Department of Psychiatry, 19 
School of Clinical Medicine, University of Cambridge  20 
Box 189, Level E4, Cambridge Biomedical Campus 21 
Cambridge, UK, CB2 0SP 22 
Email: ls514@cam.ac.uk 23 
Tel: +44(0)1223331134 24 
 25 
Short title: Longitudinal and quantitative MRI in AD 26 
 27 
 2 
 28 
Abstract 29 
Quantitative MRI provides important information about tissue properties in 30 
brain both in normal ageing and in degenerative disorders. Although it is well 31 
known that those with Alzheimer’s disease (AD) show a specific pattern and 32 
faster rate of atrophy than controls, the precise spatial and temporal patterns 33 
of quantitative MRI in AD are unknown. We aimed to investigate 34 
neuroimaging correlates of AD using serial quantitative MRI. In our study, 35 
twenty-one subjects with AD and thirty-two similar-aged healthy controls 36 
underwent two serial MRI scans at baseline and 12 months. Tissue 37 
characteristics were captured using two quantitative MRI parameters: 38 
longitudinal relaxation time (qT1) and transverse relaxation time (qT2). The 39 
two groups (AD and controls) were statistically compared using a voxel based 40 
quantification (VBQ) method based on Matlab and SPM8. At baseline, 41 
subjects with AD showed a significant reduction of qT1 and qT2 compared to 42 
controls in bilateral temporal and parietal lobes, hippocampus, and basal 43 
ganglia. This pattern was also observed at follow-up. Longitudinally, in AD we 44 
found a significant increase rather than further reduction of qT1 and qT2 from 45 
the baseline in bilateral hippocampus, thalamus and right caudate nucleus. In 46 
addition, the longitudinal change of qT1 in left hippocampus was negatively 47 
correlated with cognitive decline in AD over the 1-year period, and the general 48 
disease severity significantly predicted the amount of increase of qT1 in 49 
bilateral hippocampus over 12 months. The longitudinal change of qT2 in left 50 
parahippocampus correlated with change in neuropsychiatric features over 51 
time. In summary, quantitative MRI parameters were reduced in AD cross-52 
sectionally, but increased over time, showing distinct spatiotemporal patterns 53 
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from the atrophy in AD. We also showed the clinical relevance of quantitative 54 
MRI parameters, indicating their potential promise as new imaging markers in 55 
AD. 56 
 57 
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Introduction  63 
One of the main current research focuses on Alzheimer’s disease (AD) is 64 
early intervention, thus, there is a pressing need for reliable biomarkers for 65 
early AD detection. Existing biomarkers include cerebrospinal fluid (CSF), 66 
PET/SPECT imaging of neural metabolism and β-amyloid binding, as well as 67 
structural and functional MRI [1]. Among these techniques, MRI is 68 
noninvasive, so provides a powerful and safe tool for research and clinical 69 
diagnosis / screening, both of which are important for investigating the 70 
underlying neuropathology and early detection [2]. 71 
 72 
It has been shown that MRI not only reveals changes in brain volume and 73 
macrostructure, but also microstructural alterations in brain tissue integrity 74 
and its biochemical environment [3]. An emerging neuroimaging technique is 75 
quantitative MRI (qMRI) based on the physical measurement of longitudinal  76 
(qT1) and transverse (qT2) relaxation times. (Here we shall refer to these 77 
quantitative measurements as qT1 and qT2 to distinguish them from the more 78 
common qualitative radiological T1 or T2 weighted scans). In general, qT1 is 79 
correlated with water content and the level of myelination, and qT2 is related 80 
to chemically determined brain iron concentration [3]. 81 
 82 
Quantitative MRI provides important information about tissue properties in 83 
brain both in normal ageing [4,5], degenerative disorders such as Parkinson’s 84 
disease [6], AD and dementia with Lewy bodies (DLB) [7], and neuronal loss 85 
due to brain and spinal cord injury [8]. In our previous study of DLB using 86 
qMRI, we demonstrated that the spatial pattern in the changes of qT1 and 87 
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qT2 was different from the pattern of atrophy, thus quantitative MRI may 88 
provide incremental benefit over and above that of structural MRI [7]. We also 89 
argue that quantitative MRI may indirectly detect neuronal and molecular 90 
changes in AD that precede the structural brain damage and clinical 91 
impairments decades in time [2]. Although it is well known that those with AD 92 
show a specific pattern and faster rate of atrophy than controls, the precise 93 
spatial and temporal patterns of quantitative MRI alteration in AD are 94 
unknown.  95 
 96 
In this study, we aimed to investigate neuroimaging correlates of AD using 97 
serial quantitative MRI. In particular, we evaluated maps of qT1 and qT2 in 98 
grey matter comparing these parameters between the AD and the similarly 99 
aged control groups using the voxel-based quantification (VBQ) approach [4] 100 
both cross-sectionally and longitudinally. In addition, we explored the clinical 101 
relevance of quantitative MRI changes over a 12-month period. 102 
 103 
Materials and Methods 104 
Subjects, assessment and diagnosis 105 
Thirty-six subjects with probable AD [9] over the age of 60 were recruited from 106 
a community dwelling population of patients referred to local Old Age 107 
Psychiatry, Geriatric Medicine or Neurology Services. Thirty-five similarly 108 
aged control subjects were recruited from relatives and friends of subjects 109 
with dementia or volunteered via advertisements in local community 110 
newsletters. Twenty-one AD subjects and 32 controls underwent MR imaging 111 
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at both baseline and follow-up and are included in the analyses reported here. 112 
These subjects underwent clinical and neuropsychological evaluations at 113 
baseline and follow-up at 1 year. (The rest of subjects were not scanned at 114 
follow-up, thus excluded from the analysis.)  115 
 116 
The research was approved by Newcastle & North Tyneside 1 Research 117 
Ethics Committee (No. 05/Q0905/217). All subjects or, where appropriate, 118 
their nearest relative, provided written informed consent. Assessment of 119 
global cognitive measures at both baseline and follow-up assessments 120 
included the Cambridge Cognitive Examination (CAMCOG) [10], which 121 
incorporates the Mini-Mental State Examination (MMSE) [11]. Motor 122 
parkinsonism was evaluated with the Unified Parkinson’s Disease Rating 123 
Scale Part III (UPDRS-III) [12]. For subjects with dementia, neuropsychiatric 124 
features were evaluated with the Neuropsychiatric Inventory (NPI) [13]. 125 
 126 
MRI data acquisition  127 
Participants underwent MRI scanning on a 3T Philips Achieva MRI system 128 
with an 8-channel receiver head coil at both baseline and 12-month follow-up. 129 
Structural images were acquired using a T1 weighted volumetric sequence 130 
(3D MPRAGE, sagittal acquisition aligned with the AC-PC line, 1mm isotropic 131 
resolution, matrix 240×240×180, TR=9.6ms, TE=4.6ms, flip angle=8o, SENSE 132 
factor 2). In addition, a B0 field-map using a dual echo 3D GRE (2mm 133 
isotropic resolution, matrix 128×128×72, TR=27ms, TE=2.6/6.1ms) was 134 
acquired. 135 
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 136 
Quantitative mapping of tissue qT1 and qT2 relaxation times was performed 137 
using custom designed MRI sequences developed in-house under a research 138 
agreement with Philips Medical Systems.   139 
 140 
Fast qT1 mapping was based on the inversion recovery (IR) methods 141 
originally published by Ordidge et al [14] and expanded by Clare and Jezzard 142 
[15]. The sequence imaged 72 axial slices spanning the brain, which were 143 
grouped into 5 consecutive slabs each of thickness 24mm.  For each slab a 144 
slice selective adiabatic (sech) inversion pulse was applied to invert the 145 
magnetisation ensuring that the region of full inversion encompassed the 24 146 
mm thick section of interest.  This inversion was followed by slice selective 147 
single shot EPI readout of 12 contiguous slices of 2 mm thickness equally 148 
spaced across the slab. The first slice was imaged 250ms post inversion and 149 
subsequent slices every 205 ms thereafter.  During the repetition time (TR) of 150 
15000ms each slab was inverted and imaged with a slab order of 1,3,5,2,4 to 151 
minimise interaction between slices.  In this way the time between inverting 152 
adjacent slabs was 6000ms, sufficient to allow full relaxation of brain tissue. 153 
The sequence was repeated 12 times and on each repetition the order of 154 
acquired slices within each slab was permuted by one position, for example  155 
1,2,3,4,5,6,7,8,9,10,11,12 156 
2,3,4,5,6,7,8,9,10,11,12,1 157 
3,4,5,6,7,8,9,10,11,12,1,2 158 
etc 159 
such that the at the end of acquisitions every slice had been imaged at each 160 
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of the 12 inversion times.  Total scan time was therefore 180s for the 161 
complete IR series in 72 slices with isotropic 2mm resolution.  This sequence 162 
is shown schematically in Figure 1. 163 
 164 
Insert Figure 1 here 165 
 166 
Calculation of qT1 maps used a purpose written algorithm in Matlab, which 167 
reordered the data into incremental inversion order for each slice and then 168 
performed voxel-wise non-linear least squares fitting to the standard 3 169 
parameter model for the inversion recovery experiment: 170 
 171 
𝑆(𝑇𝐼𝑅) =  𝑆𝑜(1 −  𝛼𝑒
−𝑇𝐼𝑅
𝑞𝑇1 ) 
 172 
where TIR is the inversion time, S(TIR) is  the signal value or the data obtained 173 
from the inversion recovery experiment, qT1 is the longitudinal relaxation 174 
time, So is the proton density and  is the effective inversion efficiency .  qT1, 175 
So and were computed pixel-wise from the fitting process. Ideally is 176 
expected to be 2 but it was allowed to be a free variable in the fitting in order 177 
to increase the accuracy of the computed qT1. The 3D images of proton 178 
density S0, qT1, and the goodness of fit were saved for evaluation. 179 
 180 
Fast qT2 mapping used a multi-spin echo sequence with segmented EPI 181 
readout based around a Gradient and Spin Echo Imaging sequence. The 182 
sequence collected 8 spin echoes with equal spacing of 20ms and 5 gradient 183 
recalled echoes per spin echo (EPI factor 5) to accelerate image collection.  184 
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Repetition time was set to 4700ms and 72 slices were collected in standard 185 
interleaved acquisition (2mm isotropic resolution, matrix 128×128).  Total 186 
scan time was 120s. 187 
 188 
Calculation of qT2 maps again used a purpose written algorithm in Matlab, 189 
which performed voxel-wise non-linear least squares fitting to the standard 2 190 
parameter model for transverse relaxation. 191 
 192 
𝑆(𝑇𝐸) =  𝑆𝑜𝑒
−𝑇𝐸
𝑞𝑇2  
 193 
where TE is the echo time, qT2 is the transverse relaxation time and So is the 194 
proton density.  qT2, and So were computed pixel-wise from the fitting 195 
process. The 3D images of proton density So, qT2, and the goodness of fit 196 
were saved for evaluation. 197 
 198 
Scans were collected using both sequences in aqueous and gel based test 199 
objects of known qT1 and qT2 and compared to data collection using a single 200 
slice inversion recovery sequence for qT1 and a single slice Carr-Purcell 201 
Meiboom-Gill (CPMG) sequence for qT2 to validate the method. 202 
 203 
Statistical Tests of Demographic, clinical, and cognitive measures. 204 
Group characteristics were evaluated with Statistical Toolbox of Matlab 205 
(www.mathworks.co.uk/products/statistics). Differences in demographic and 206 
clinical data were assessed with use of either t-tests for continuous variables 207 
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or χ2 tests for categorical measures. For each test statistic, a probability value 208 
of p<0.05 was regarded as significant.  209 
 210 
Voxel-based quantification 211 
MRI data processing was performed in a combined FSL 212 
(fsl.fmrib.ox.ac.uk/fsl/fslwiki) and SPM (www.fil.ion.ucl.ac.uk/spm) based on 213 
the previously validated voxel-based quantification (VBQ) procedure [4]. At 214 
both baseline and follow-up, raw qT1 and qT2 imaging datasets were 215 
corrected for field inhomogeneities using B0 maps and the PRELUDE/FUGUE 216 
algorithm in FSL [16]. Then, the bias corrected qT1 and qT2 maps were used 217 
for subsequent analysis. 218 
 219 
Volumetric structural T1 weighted images were firstly segmented using 220 
Gaussian mixture model implemented in the VBM toolbox [17], and brain 221 
tissues were classified into grey matter (GM), white matter (WM) and 222 
Cerebrospinal fluid (CSF) for both baseline and follow-up. A conjunction GM 223 
brain mask was generated for each individual subject (in both AD and control 224 
groups) by computing the intersection between the GM probability maps at 225 
the baseline and that at the follow-up of the same subject, and then 226 
thresholded at p>0.5 in each participant’s native space. This mask was used 227 
to select a common area of GM tissue at both baseline and follow-up in order 228 
to ensure there were equal number of voxels tested in both time points, thus 229 
avoiding potential bias in the statistical analysis. 230 
 231 
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As in standard longitudinal VBM procedure, only the baseline GM probability 232 
maps were non-linearly normalized to standard MNI space 233 
(www.mni.mcgill.ca) using the diffeomorphic registration algorithm (DARTEL)  234 
[17] in SPM, and the resulting parameters were used to normalize the qT1 235 
and qT2 maps in both baseline and follow-up. The qT1 and qT2 maps at both 236 
time points were firstly co-registered with the GM probability maps derived 237 
from structural T1 images at baseline, then the thresholded conjunction GM 238 
brain masks were applied to qT1 and qT2 data at both time points. Finally, we 239 
transformed the GM maps of qT1 and qT2 MRI parameters into standard MNI 240 
space using the participant-specific diffeomorphic parameters estimated from 241 
the baseline scans based on the previous DARTEL procedure. However, we 242 
did not apply modulation to these quantitative MRI parameters in order to 243 
avoid confound of age and disease related GM volume changes. Finally, all 244 
normalized quantitative qT1 and qT2 maps were smoothed with an isotropic 245 
Gaussian kernel of 6 mm full width at half maximum.  246 
 247 
For statistical analysis investigating disease induced regional microstructural 248 
alterations between the AD and control groups, and between the baseline and 249 
follow-up, we used the General Linear Model (GLM) with age and gender as 250 
covariates. Then, two-tailed t-tests were performed at each voxel to detect 251 
voxel-wise difference between the groups or time points. We also tested the 252 
group x time interaction using a mixed model ANOVA. The false positive rate 253 
was controlled using family-wise error (FWE) correction for multiple 254 
comparisons, and thresholded at p<0.05 at the cluster level.  255 
 256 
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Post-hoc region-of-interest analysis 257 
To explore the clinical relevance of qT1 and qT2, in a post-hoc region-of-258 
interest (ROI) analysis, we extracted the averaged quantitative MRI values 259 
from significant clusters found in the longitudinal comparison. Here, we used 260 
the unsmoothed maps in order to preserve the original values of the MR 261 
parameters. Then, we correlated cognitive and clinical measures with the 262 
averaged quantitative MRI values extracted from the significant clusters 263 
obtained from the previous group comparisons. These measurements 264 
included the CAMCOG, MMSE, UPDRS III and NPI total scores. Multiple 265 
comparisons were controlled using Bonferroni correction for the number of 266 
ROIs. 267 
 268 
Results 269 
Demographic clinical and cognitive measures 270 
As shown in Table 1, there were no significant differences between AD and 271 
control groups for age, sex and educational level. However, as expected, the 272 
two groups significantly different at both baseline and follow-up for UPDRS III, 273 
NPI, MMSE and CAMCOG scores with subjects with AD scoring poorer in all 274 
measures compared to the controls. 275 
 276 
Insert Table 1 here 277 
 278 
Cross-sectional comparison of qT1: AD vs. controls 279 
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As shown in Figure 2A and Table 2A, at the baseline, we found a significant 280 
decrease in qT1 for the AD group compared to controls (p<0.0001, FWE) in 281 
bilateral temporal, parietal and occipital lobes, as well as several subcortical / 282 
striatal nuclei. Largest significant clusters were within bilateral hippocampus, 283 
parahippocampus, cuneus, precuneus, caudate and putamen. At the follow-284 
up, we found a very similar pattern of qT1 changes comparing between AD 285 
and control groups. See Figure 2B and Table 2B. No significant increase in 286 
qT1 was found for the AD group compared to controls at either baseline or 287 
follow-up. 288 
 289 
Insert Table 2 here 290 
 291 
Insert Figure 2 here 292 
 293 
Cross-sectional comparison of qT2: AD vs. controls 294 
For qT2 at the baseline, we also found a significant decrease for the AD group 295 
compared to controls (p<0.0001, FWE) in left superior and right middle 296 
temporal lobes, bilateral hippocampus and left parahippocampus as shown in 297 
Figure 3A and Table 3A. At the follow-up, we found a very similar pattern of 298 
qT2 changes comparing between AD and control groups except for a cluster 299 
covering left caudate, putamen and pallidum, and a right cuneus cluster, 300 
which were not seen at the baseline. See Figure 3B and Table 3B. No 301 
significant increase in qT2 was found for the AD group compared to controls 302 
at either baseline or follow-up. 303 
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 304 
Insert Table 3 here 305 
 306 
Insert Figure 3 here 307 
 308 
Longitudinal comparison of qT1: baseline vs. follow-up 309 
When comparing qT1 between baseline and follow-up in the AD group, we 310 
found a significant increase over 12 months in bilateral hippocampus and 311 
parahippocampus (p<0.0001, FWE), thalamus (p<0.0001 for left and p=0.002 312 
for right, FWE) and right caudate (p<0.0001, FWE) as shown in Figure 2C 313 
and Table 4A. The significant hippocampus clusters in the longitudinal 314 
comparison are more medial to the clusters found in the cross-sectional 315 
comparisons; see Figure 2. We found no longitudinal change for qT1 in the 316 
control group and no group (AD and controls) x time (baseline and follow-up) 317 
interaction. 318 
 319 
Insert Table 4 here 320 
 321 
Longitudinal comparison of qT2: baseline vs. follow-up 322 
For qT2, we found a significant increase between the baseline and the follow-323 
up in the AD group as shown in Figure 3C and Table 4B. Significant clusters 324 
are located in left parahippocampus (p<0.0001, FWE), right caudate, putamen 325 
and insula (p<0.0001, FWE), as well as right middle frontal lobe (p=0.002, 326 
FWE). We found a significant group x time interaction in right insula 327 
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(p<0.0001, FWE, Table 4C) bordering with right putamen and extending to 328 
right caudate at lower threshold (p<0.001, uncorrected). We argue that 329 
atrophy is unlike the explanation of this effect because if atrophy were a driver 330 
of an increase in qT2 over time, we would expect AD subjects at baseline to 331 
have a greater qT2 than controls because of their greater atrophy, a result 332 
opposite to what we found here. 333 
 334 
For the control group, we found a significant longitudinal increase in qT2 335 
(p<0.0001, FWE) in left superior parietal lobe, caudate head, and 336 
supplementary motor area extending to superior medial prefrontal cortex. 337 
(See Figure 3D.)  338 
 339 
Correlation between cognitive / clinical measures and quantitative MRI 340 
Here, the main focus is on the relationship between longitudinal changes in 341 
quantitative MRI parameters and cognitive / clinical measures in the AD group 342 
at baseline, follow-up and change over the 1-year period. Thus for qT1, we 343 
have defined three region-of-interest (ROIs) based on the results of the 344 
longitudinal comparison of qT1, i.e. left / right hippocampus and right caudate. 345 
We found a significant negative correlation between the longitudinal changes 346 
in qT1 in left hippocampus and the cognitive decline (i.e. change in total 347 
MMSE score over the 1-year period) in AD (r=-0.58, p=0.006). We found a 348 
significant correlation between baseline CAMCOG score and the changes of 349 
qT1 in bilateral hippocampus over the 1-year period. In addition, a significant 350 
correlation was found between baseline UPDRS III score and the longitudinal 351 
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changes of qT1 in bilateral hippocampus. Both effects were stronger in the 352 
right hemisphere than in the left and only the right hippocampus survived the 353 
correction for multiple comparisons. (See Table 5A.) Nonetheless, this 354 
suggests that baseline CAMCOG and UPDRS scores predict changes in qT1 355 
in these regions, that is, the more severe the dementia in general, the more 356 
qT1 increases.  357 
 358 
We also found a significant correlation between qT1 in right caudate and 359 
UPDRS score cross-sectionally at both baseline (r=0.60, p=0.004) and follow-360 
up (r=0.51, p=0.018) in AD. Moreover, qT1 in right hippocampus was 361 
significantly correlated with the CAMCOG score only at the follow-up (r=-0.60, 362 
p=0.004) but not at the baseline. (See Table 5A.) No other correlation 363 
survived the correction for multiple comparisons.  364 
 365 
Insert Table 5 here 366 
 367 
For qT2, we have extracted qMRI values from four significant clusters found in 368 
the longitudinal comparison: right insula extending to putamen, left 369 
parahippocampus, right caudate and right superior medial frontal cortex 370 
(BA8). We found a significant correlation between the longitudinal changes of 371 
qT2 in left parahippocampus and the changes in NPI score over time (r=0.54, 372 
p=0.012) in AD. (See Table 5B.) No other correlation was found. 373 
 374 
Individual analysis in longitudinal comparison 375 
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Figure 4 shows the individual variability in longitudinal changes in quantitative 376 
MRI within the AD group, and how it relates to disease severity. It can be 377 
seen in Figure 4A that subjects with AD showed a general increase in qT1 in 378 
right hippocampus, and the rate of increase seems to accelerate in moderate 379 
and severe cases of AD, i.e. baseline MMSE score lower than 20. The same 380 
pattern was observed in other clusters found in the longitudinal analysis. 381 
Figure 4B shows the individual changes in qT2 in left parahippocampus over 382 
time. We have found a very similar trend as in qT1 with subjects with AD 383 
generally showing an increase in qT2 over 12 months. We have also found 384 
similar pattern in other significant clusters derived in the longitudinal analysis 385 
in the AD group.   386 
 387 
Insert Figure 4 here 388 
 389 
Discussion 390 
Using novel longitudinal and quantitative MRI method and voxel-based 391 
quantification, we showed that at the cross-sectional level, qT1 and qT2 in AD 392 
were significantly decreased in multiple cortical areas in bilateral temporal and 393 
parietal lobes with the largest changes in medial temporal structures 394 
comparing to similarly aged control subjects at baseline. This pattern is 395 
consistent with previous neuroimaging studies with AD showing significant 396 
volume reduction in these regions such as hippocampal, enthorinal and 397 
parahippocampal cortices [18].  398 
 399 
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At follow-up, we found a very similar pattern of quantitative MRI changes in 400 
both qT1 and qT2 comparing AD and control groups with the main affected 401 
brain areas in bilateral hippocampus and associated structures. This 402 
demonstrates the robustness of qMRI in reproducing a consistent pattern of 403 
quantitative MRI parameter changes at two different time points with 12 404 
months gap.  405 
 406 
It is worth noting that both qT1 and qT2 parameters consistently picked up 407 
substantial changes in subcortical regions, e.g. bilateral caudate, putamen 408 
and thalamus. However, comparing to neocortex, in particular the 409 
hippocampus, these basal nuclei and thalamus have received much less 410 
attention in previous research, and conventional volumetric MRI showed a 411 
mixed picture of atrophy in these subcortical areas. For example, atrophy of 412 
putamen was found in DLB but not in AD [19], whereas putamen and thalamic 413 
atrophy were both shown in AD in a different study [20] reflecting a relatively 414 
high level of noise in volumetric measures in these regions and large inter-415 
study variability. In contrast, quantitative MRI may detect neuronal and 416 
macromolecular changes in tissue environment, which does not rely on 417 
atrophy shown in structural T1 weighted MRI. Based on this, we argue that 418 
qMRI provides incremental benefit over and above that of structural MRI. 419 
Quantitative MRI also offers a unique opportunity to detect early brain 420 
changes in AD before observable brain volume reduction can be reliably 421 
shown and cognitive / clinical impairments can be found [2].  422 
 423 
Although we found that AD was characterized by a reduction in qMRI 424 
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parameters in cross-sectional comparison, in longitudinal comparison, we 425 
found that qT1 was increased rather than decreased in right caudate, bilateral 426 
hippocampus and parahippocampus, as well as in thalamus. We also found 427 
that qT2 was increased in right caudate, putamen and insula in addition to left 428 
parahippocampus in AD. Frontal changes in qT2 over time were also notable 429 
in AD. This spatial pattern is consistent with the development of atrophy in AD 430 
[21]. Increase in qT2 was found in healthy controls in left superior parietal 431 
lobe, left caudate head, and bilateral supplementary motor area extending to 432 
superior medial prefrontal cortex. However, none of these brain regions 433 
overlap with longitudinal qT1 / qT2 changes found in AD suggesting the 434 
increase of qT2 in AD and controls may reflect distinct underlying causes. The 435 
only significant group x time interaction was found in right insula extending to 436 
putamen and caudate nucleus.  437 
 438 
To further understand the increase in qMRI over time in AD, we performed an 439 
individual analysis, which showed the changes of qT1 and qT2 over time in 440 
hippocampus, caudate and other clusters found in the longitudinal 441 
comparison. By sampling individual subjects that were at different stages of 442 
the disease indicated by their severity (i.e. baseline MMSE), we have pictured 443 
an overall trajectory of qT1 and qT2 in clinically diagnosed AD. It is notable 444 
that the rate of qMRI increase was slow at early stages of AD but accelerated 445 
at severe stage of AD. Thus, although qT1 and qT2 decreased in AD 446 
comparing with controls at the cross-section level, it is possible that qT1 and 447 
qT2 may increase over time in AD because plaque burden may stabilize or 448 
even fall in established stages of AD as the disease progresses. In addition, 449 
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we found that general disease severity (measured by different but related 450 
scales, i.e. CAMCOG and UPDRS) predicts the rate of change in qT1 in 451 
hippocampus showing a faster rate of increase at the severe stage of AD.  452 
 453 
These changes in qMRI followed a trend that mirrors the inverted ‘U’ shape 454 
trajectory of brain β-amyloid over time [22] suggesting that at the severe stage 455 
of AD the brain β-amyloid (and/or other factors) may undergo a decrease. A 456 
more quantitative treatment of the parallels between the current results and 457 
the findings by Jack et al will require a deeper analysis of how the very 458 
different properties of the two might reflect how brain β-amyloid burden is 459 
captured by each imaging method, and the consequences of this for temporal 460 
trajectory of these variations. This analysis is outside the scope of the current 461 
paper, and the comparisons we provide here should be regarded as 462 
preliminary and illustrative. However, it is clear that such a ‘U’ shaped 463 
temporal pattern has not been found in atrophy in AD. 464 
 465 
In addition, we showed the clinical relevance of quantitative MRI parameters 466 
in AD, i.e. the change of qT1 at left hippocampus was correlated with 467 
cognitive decline (annual changes in MMSE score) in AD. For qT2, the 468 
longitudinal change in right parahippocampus was significantly correlated with 469 
the annual changes in neuropsychiatry condition (NPI) in AD over time. In 470 
addition, we found a significant correlation between qT2 in right caudate 471 
nucleus and parkinsonism (UPDRS score) at the cross-sectional level (at both 472 
baseline and follow-up), suggesting the AD pathology may be present in basal 473 
ganglia structures, therefore causing motor parkinsonism in AD. Here, it is 474 
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interesting to see that qT2 in caudate was sensitive to the changes in UPDRS 475 
scores. This finding is also consistent with Wilson et al. [23], which showed 476 
that parkinsonian signs are strong predictors for the progression of AD. 477 
 478 
In our previous cross-sectional study on dementia with Lewy bodies (DLB), 479 
we also found a significant reduction of qMRI parameters in DLB compared to 480 
controls [7]. In addition, we showed that the spatial pattern of qMRI alteration 481 
only partly overlapped with that of atrophy, making the latter an unlikely 482 
explanation for the qMRI decreases. In the current study, we have followed 483 
the similar analysis procedure in order to avoid partial volume effect due to 484 
atrophy. In seeking the possible underlying biochemical interpretation of these 485 
quantitative MRI parameters and their evolution over time, qT1 is 486 
predominantly influenced by water content but also relates to the degree of 487 
myelination [24,25,26]. Both qT1 and qT2 are also sensitive to the level of 488 
iron, which is present in amyloid plaques [27] and in microbleeds.   489 
 490 
Although it is not possible to precisely determine the pathological changes 491 
associated with alterations in qT1 or qT2 in AD, it has been suggested that 492 
decreases in qT1 and qT2 might be associated with increases in amyloid 493 
burden and iron load in the brain based on histologically confirmed animal 494 
model of AD [28,29]. Consistent with our finding, decreased qT1 was found to 495 
be associated with an increase in β-amyloid deposition in 5xFAD transgenic 496 
mouse model of Alzheimer’s disease compared with wild type mice [30]. In 497 
addition, decreased qT2 was found in APP/PS1 transgenic mouse model of 498 
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AD [31,32] probably reflecting a complex interaction between β-amyloid and 499 
iron concentration as well as other factors.  500 
 501 
In a longitudinal study of β-amyloid plaque development in Tg2576 transgenic 502 
mice using qT2 relaxation time [33], it has been found that qT2 decreases 503 
with age (12 - 18 months) following an increase in plaque area, number and 504 
size in the brain. Although it is difficult to match the disease stage of the 505 
mouse model to humans with AD and it is not common to find atrophy in the 506 
animal model of AD, this finding is nonetheless consistent with our results 507 
showing decreased qT2 in medial temporal lobes in AD. It has also been 508 
shown in a study based on APP/PS1 transgenic mice model that qT2 is 509 
modulated by the level of amyloid in subiculum without histochemically 510 
detectable iron in the brain [34], providing promises in detecting the 511 
pathological process in AD at the earliest stages.  512 
 513 
In addition to our previous findings on qMRI changes in DLB [7], as well as 514 
the established literature on animal qMRI correlates, the current data provided 515 
convergent evidence for the potential ability of quantitative MRI in detecting 516 
early changes of tissue property caused by neurodegenerative disease. Being 517 
able to apply this novel technique in human using relatively safe MRI method 518 
enables new means for early detection of AD and tracking its progression 519 
over time. This approach is also likely to close the gap between animal 520 
models of amyloidosis and studies on human AD in the context of drug 521 
discovery. 522 
 523 
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Conclusion 524 
In summary, quantitative MRI parameters were reduced in AD cross-525 
sectionally, but increased over time, showing distinct spatiotemporal patterns 526 
from the atrophy in AD. Our findings are consistent with animal model of AD 527 
showing quantitative MRI can provide information, which may reflect 528 
pathology such as amyloid burden and iron load. We also showed the clinical 529 
relevance of quantitative MRI, indicating their potential promise as new early 530 
imaging markers in AD. With reduced radiation, MRI is more suited for 531 
longitudinal studies than PET. Thus, longitudinal and quantitative MRI will be 532 
valuable in developing new treatments by tracking brain changes associated 533 
AD in vivo. 534 
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Table 1. Demographics, clinical and neuropsychological measures. 
Values expressed as Mean ± 1SD. Abbreviations: AD = Alzheimer’s disease; HC = Healthy control; UPDRS III = Unified 
Parkinson’s Disease Rating Scale, Part III; NPI Total = Neuropsychiatry Inventory; MMSE = Mini-Mental State examination; 
CAMCOG = Cambridge Cognitive Examination. 
 
 
 
 
HC (N=32) 
 
AD (N=21) 
 
p value 
    
Gender (m:f) 19:13 12:9 Χ2=0.03, p=0.87 
Age (yrs) 76.6 ± 5.3 77.0 ± 5.4 t51=-0.3, p=0.76 
Education (yrs) 11.9 ± 2.7 11.5 ± 3.9 t51=0.45, p=0.65 
UPDRS III 
   Baseline 1.8 ± 1.6 4.3 ± 3.5 t51=-3.6, p<0.001 
   Follow-up 1.5 ± 1.7 5.1 ± 4.5 t51=-4.1, p<0.001 
NPI Total  
  Baseline  19.7 ± 11.2  
  Follow-up  15.5 ± 12.7  
MMSE    
   Baseline 29.2 ± 0.9 20.6 ± 4.2 t51=11.3, p<0.001 
   Follow-up 29.3 ± 0.9 19.2 ± 4.2 t51=13.2, p<0.001 
CAMCOG 
  Baseline 97.9 ± 3.4 69.4 ± 12.1  t51=12.7, p<0.001 
  Follow-up 98.5 ± 2.8 63.9 ± 15.0 t51=12.8, p<0.001 
    
Table 2 Significantly different clusters for qT1 at (A) baseline and (B) follow-up comparing the AD and control groups. FWE 
corrected, p < 0.05. (Only clusters with k > 300 are shown.) 
Cluster level p 
FWE-Corr 
Extent 
(k) 
T MNI 
coordinates 
(x,y,z) 
Anatomical region 
 
(A) baseline: Controls > AD 
< 0.0001 11950 10.06 30, -9, -18 Right hippocampus & parahippocampus 
< 0.0001 12023 9.69 -34, -34, -9 Left hippocampus & parahippocampus  
< 0.0001 1442 9.94 15, -69, 27 Right cuneus & precuneus 
< 0.0001 759 6.52 21, 17, -5 Right caudate & putamen  
< 0.0001 577 6.83 -12, -67, 21 Left cuneus & precuneus 
< 0.0001 302 5.69 32, -76, 28 Right middle occipital lobe 
 
(B) follow-up: Controls > AD  
< 0.0001 13161 9.69 30, -9, -18 Right hippocampus & parahippocampus 
< 0.0001 9192 9.72 -34, -34, -9 Left hippocampus & parahippocampus  
< 0.0001 997 7.53 -6, 8, -3 Left caudate & putamen 
< 0.0001 620 6.64 21, 17, -5 Right caudate & putamen  
< 0.0001 550 6.78 -14, -69, 19 Left cuneus & precuneus 
< 0.0001 467 7.31 -26, -72, 36 Left superior occipital lobe 
< 0.0001 393 7.24 -45, -58, 30 Left angular gyrus 
Table 3 Significantly different clusters for qT2 at (A) baseline and (B) follow-up comparing the AD and control groups. FWE 
corrected, p < 0.05. (Only clusters with k > 50 are shown.) 
Cluster level p 
FWE-Corr 
Extent 
(k) 
T MNI 
coordinates 
(x,y,z) 
Anatomical region 
 
(A) baseline: Controls > AD 
< 0.0001 153 7.11 -34, -33, -9 Left hippocampus & parahippocampus 
< 0.0001 103 7.09 30, -10, -17 Right hippocampus 
< 0.0001 60 6.23 -51, -4, 1 Left superior temporal lobe 
< 0.0001 59 6.48 -28, -10, -17 Left hippocampus 
< 0.0001 55 6.71 60, -28, -2 Right middle temporal lobe  
 
(B) followup: Controls > AD 
< 0.0001 229 7.12 -8, 9, -5 Left caudate, putamen & pallidum 
< 0.0001 221 7.38 60, -28, -2 Right middle temporal lobe 
< 0.0001 162 7.39 12, -70, 28 Right cuneus  
< 0.0001 156 7.66 -33, -33, -8 Left hippocampus & parahippocampus 
< 0.0001 65 6.19 62, -21, 13 Right middle temporal lobe 
< 0.0001 62 5.84 24, 6, -24 Right hippocampus 
Table 4 Significantly different clusters comparing the baseline and follow-up in the AD group for (A) qT1 and (B) qT2, as well as (C) 
significant time x group interaction for qT2. FWE corrected, p < 0.05. (Only clusters with k > 30 are shown when there is more than 
one cluster.) 
Cluster level p 
FWE-Corr 
Extent 
(k) 
T MNI 
coordinates 
(x,y,z) 
Anatomical region 
(A) AD: follow-up > baseline for qT1 
< 0.0001 476 7.15 21, -6, 21 Right caudate 
< 0.0001 327 6.73 28, -30, -8 Right hippocampus & parahippocampus 
< 0.0001 114 6.97 -22, -37, -3 Left hippocampus & parahippocampus 
< 0.0001 55 6.08 -6, -15, 10 Left thalamus  
0.002 33 5.86 12, -19, 12 Right thalamus  
(B) AD: follow-up > baseline for qT2 
< 0.0001 230 7.47 40, 3, -3 Right putamen & insula 
< 0.0001 77 6.41 -24, -22, -24 Left parahippocampus 
< 0.0001 64 5.91 18, -6, 21 Right caudate 
0.002 30 5.86 30, 17, 49 Right middle frontal lobe (BA8) 
(C) time x group interaction for qT2 
0.029 2 5.35 39, 3, -3 Right insula (extending to putamen and 
caudate at lower threshold of p < 0.001 
uncorrected) 
Table 5 Correlation between longitudinal changes in qT1 / qT2 and cognitive / clinical ratings in AD.  Abbreviations: CAMCOG = 
Cambridge Cognitive Examination; MMSE = Mini-Mental State examination; UPDRS III = Unified Parkinson’s Disease Rating 
Scale, Part III; NPI Total = Neuropsychiatry Inventory. ** significant correlation corrected for multiple comparisons, * significant 
correlation uncorrected.  
 
(A) qT1 
 Left hippocampus 
(follow-up - baseline) 
Right hippocampus 
(follow-up - baseline) 
Right caudate 
(follow-up - baseline) 
CAMCOG (baseline) r = -0.49, p = 0.026 * r = -0.58, p = 0.006 ** r = -0.16, p = 0.492 
CAMCOG (follow-up - baseline) r = -0.37, p = 0.102 r = -0.27, p = 0.236 r = -0.30, p = 0.194 
MMSE (baseline) r = 0.006, p = 0.980 r = -0.29, p = 0.198 r = -0.09, p = 0.703 
MMSE (follow-up - baseline) r = -0.58, p = 0.006 ** r = -0.30, p = 0.183 r = -0.31, p = 0.167 
UPDRS III (baseline) r = 0.46, p = 0.035 * r = 0.55, p = 0.009 ** r = 0.07, p = 0.764 
UPDRS III (follow-up - baseline) r = -0.05, p = 0.829 r = 0.08, p = 0.737 r = 0.13, p = 0.585 
NPI (baseline) r = 0.17, p = 0.469 r = 0.15, p = 0.521 r = 0.12, p = 0.595 
NPI (follow-up – baseline) r = -0.24, p = 0.290 r = -0.12, p = 0.593 r = 0.16, p = 0.492 
 
(B) qT2 
 Right putamen / insula  
(follow-up - baseline) 
Left parahippocampus 
(follow-up - baseline) 
Right caudate  
(follow-up - baseline) 
Right BA8  
(follow-up - baseline) 
CAMCOG (baseline) r = -0.30, p = 0.183 r = -0.19, p = 0.420 r = -0.24, p = 0.289 r = -0.27, p = 0.237 
CAMCOG (follow-up - baseline) r = -0.17, p = 0.459 r = 0.04, p = 0.879 r = 0.19, p = 0.414 r = -0.14, p = 0.548 
MMSE (baseline) r = -0.14, p = 0.537 r = -0.07, p = 0.748 r = -0.22, p = 0.339 r = -0.11, p = 0.640 
MMSE (follow-up - baseline) r = -0.21, p = 0.357 r = -0.09, p = 0.702 r = 0.15, p = 0.508 r = -0.07, p = 0.750 
UPDRS III (baseline) r = 0.007, p = 0.975 r = -0.15, p = 0.526 r = 0.16, p = 0.483 r = 0.13, p = 0.590 
UPDRS III (follow-up - baseline) r = -0.10, p = 0.681 r = 0.04, p = 0.871 r = -0.10, p = 0.656 r = -0.21, p = 0.353 
NPI (baseline) r = 0.13, p = 0.564 r = -0.12, p = 0.590 r = -0.22, p = 0.335 r = 0.30, p = 0.181 
NPI (follow-up – baseline) r = 0.16, p = 0.500 r = 0.54, p = 0.012 ** r = 0.10, p = 0.681  r = -0.02, p = 0.946   
Figure 1 Schematic diagram of quantitative T1 mapping sequence 
 
 
 
Figure 2 Significant clusters in the cross-sectional comparison showing the 
areas of qT1 decreases in AD compared to age matched controls at (A) 
baseline and (B) follow-up. (C) Significant clusters in the longitudinal 
comparison showing areas of qT1 increases in the AD group over time. FWE 
corrected, p < 0.05. 
 
 
 
Figure 3 Significant clusters in the cross-sectional comparison showing the 
areas of qT2 decreases in AD compared to age matched controls at (A) 
baseline and (B) follow-up. Significant clusters in the longitudinal comparison 
showing areas of qT2 increases in (C) the AD and (D) the control groups over 
time. FWE corrected, p < 0.05. 
 
 
 
 
 
Figure 4 Individual subject’s averaged (A) qT1 in right hippocampus and (B) 
qT2 in left paraphippocampus areas (based on the significant cluster in the 
longitudinal comparison) in AD, showing a trend of increase in qT1 / qT2 over 
time. For each line, the starting point (the left end) is determined by the 
subject’s baseline MMSE score and the qMRI values at baseline. The end 
point of each line is set by the subject’s follow-up MMSE score and the qMRI 
values at follow-up. 
 
 
